Vemurafenib in patients with BRAFV600 mutation-positive metastatic melanoma: final overall survival results of the randomized BRIM-3 study.
Annals of oncology : official journal of the European Society for Medical Oncology | 2017-10-01 | PMID 28961848
Chapman P B, Robert C, Larkin J and 15 more
